Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin
Abstract Therapeutic protocols including EGFR antibodies in the context of oxaliplatin-based regimens have variable clinical effect in colorectal cancer. Here, we tested the effect of the EGFR antibody cetuximab in different sequential combinations with oxaliplatin on the growth of colorectal cancer...
Guardado en:
Autores principales: | Elli Narvi, Katri Vaparanta, Anna Karrila, Deepankar Chakroborty, Sakari Knuutila, Arto Pulliainen, Maria Sundvall, Klaus Elenius |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6509ba9e46f9450ab57d53a05d5f7f52 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cetuximab-modified CuS nanoparticles integrating near-infrared-II-responsive photothermal therapy and anti-vessel treatment
por: Li B, et al.
Publicado: (2018) -
Gold nanoparticles affect the antioxidant status in selected normal human cells
por: Daems N, et al.
Publicado: (2019) -
Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
por: Kate S, et al.
Publicado: (2019) -
Tumor-specific delivery of therapeutic siRNAs by anti-EGFR immunonanoparticles
por: Kim JS, et al.
Publicado: (2018) -
Value and significance of brain radiation therapy during first‐line EGFR‐TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique
por: Yangchun Gu, et al.
Publicado: (2021)